Lanean...
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
BACKGROUND: In the past few years, new drugs made their appearance in the first-line setting of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among them. The present systematic review aims to point out any evidence published to date about first-line treatment with cab...
Gorde:
| Argitaratua izan da: | Cancer Manag Res |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6159801/ https://ncbi.nlm.nih.gov/pubmed/30288108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S160485 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|